化疗-免疫治疗时代广泛期小细胞肺癌中巩固性胸部放疗与预防性脑放疗的作用
基于美国国家癌症数据库(NCDB)2017—2019年数据,分析接受系统治疗(化疗或化疗-免疫治疗)的广泛期小细胞肺癌患者中放疗对总生存的影响。多因素分析显示胸部放疗、脑放疗及两者联合的HR分别为0.80、0.77、0.70,免疫治疗HR为0.87。倾向性匹配后各亚组放疗对OS的获益一致,联合胸部与预防性脑放疗似乎优于任一单独放疗。
要点
- 接受系统治疗的广泛期小细胞肺癌患者中,胸部放疗、脑放疗及两者联合的OS HR分别为0.80、0.77、0.70。
- 倾向性匹配后化疗±免疫治疗、化疗-免疫治疗、单纯化疗亚组中胸部放疗HR均为0.68,脑放疗HR为0.72/0.72/0.70。
- 联合胸部与预防性脑放疗的HR在三个亚组均为0.60,似乎优于任一单独放疗。
核心结论
- 达到候选标准并接受放疗的广泛期小细胞肺癌患者,与仅接受化疗或化疗-免疫治疗的患者相比,总生存可能显著改善。
- 联合胸部与预防性脑放疗似乎优于任一单独放疗。
- 放疗(无论一个或两个部位)的影响可能比化疗基础上加免疫治疗更有益。
研究设计与样本
- 查询美国国家癌症数据库(NCDB)2017—2019年数据。
- 接受系统治疗(化疗或化疗-免疫治疗)的患者须随访至少6个月且诊断时无脑转移。
- 所有放疗患者须接受 upfront 系统治疗、在诊断后2—6个月内接受治疗,脑放疗仅接受25 Gy分10次。
- 采用多因素分析(MVA)确定与OS相关的因素及放疗选择因素,并对影响OS的因素进行倾向性匹配以生成Kaplan-Meier OS曲线。
- 采用对数秩检验确定放疗对OS影响的Kaplan-Meier生存曲线差异。
主要发现
- 接受放疗/系统治疗与仅系统治疗的患者总数及中位随访(月)分别为890例、17.0个月和6898例、14.0个月。
- 系统治疗和放疗开始的中位时间分别为22.9天和152天。
- 多因素分析显示放疗对OS的影响(胸部、脑、脑/胸部联合的HR分别为0.80、0.77、0.70)大于其他干预包括免疫治疗(HR 0.87)和无放疗的姑息治疗(HR 1.06)。
- 放疗选择显著取决于影响OS的因素(HR),包括无肝转移、女性、年龄和Charlson合并症指数,但不取决于保险状态、种族或县收入/高中毕业率。
- 倾向性评分匹配后的OS曲线显示放疗对OS的显著影响在接受化疗±免疫治疗、化疗-免疫治疗和单纯化疗者中一致,胸部放疗HR分别为0.68/0.68/0.68,脑放疗HR分别为0.72/0.72/0.70,脑/胸部放疗HR分别为0.60/0.60/0.60。
关键数值与推荐
- 放疗患者脑放疗仅接受25 Gy分10次。
- 放疗须在诊断后2—6个月内开始。
- 系统治疗患者须随访至少6个月且诊断时无脑转移。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The role of consolidative thoracic and prophylactic brain radiation for extensive stage small cell lung cancer patients is controversial. We investigated the factors associated with the use of any radiation therapy (RT) and whether RT has a benefit to overall survival (OS) in patients receiving any systemic therapy and whether this benefit is the same if Chemotherapy (CT) or chemo-immunotherapy (CT-IO) is used. MATERIAL/METHODS: The NCDB database was queried from years 2017-2019. Patients receiving systemic therapy- STX (CT or CT-IO) had to have at least 6 months of follow-up and have no brain metastases at diagnosis. All RT patients had to receive upfront systemic therapy, be treated 2-6 months from diagnosis, and if treated to the brain received 25 Gy in 10 fractions only. Multi-variable analyses (MVA) were used to determine factors associated with OS and selection for any radiation. Propensity matching for factors affecting OS were used to generate Kaplan-Meier OS curves. Log-rank tests were used to determine differences in Kaplan Meier survival curves for the effects of RT on OS. RESULTS: The total number of patients receiving RT/STX or STX alone as well as their median follow-up (months) were (890, 17.0 mn) and (6898, 14.0mn). The median time to the start of STX and RT were 22.9 days and 152 days, respectively. MVA noted that RT had a greater effect on OS (Thorax, Brain, Both Brain/Thorax - HRs = 0.80, 0.77, 0.70) than other interventions including IO (HR 0.87) and palliative care without RT (HR 1.06). Selection for radiation depended significantly upon factors affecting OS (HR) including lack of liver metastases, females, age and Charlson co-morbidity index, but did not depend upon insurance status, race, or county income/high school graduation rates. Propensity-score matched OS curves noted the same significant effects of RT on OS in those receiving CT +/- IO, CT-IO, and CT alone with HRs of 0.68/0.68/0.68 for thoracic RT, 0.72/0.72/0.70 for brain RT, and 0.60/0.60/0.60 for brain/thoracic RT, respectively. CONCLUSIONS: The patient with extensive stage small cell lung cancer who reach candidacy and receive RT may have a significant improvement in OS compared to the patients treated only with CT or CT-IO. Combined thoracic and prophylactic brain RT seems to be better than either one alone. The impact of radiation whether given to one or two sites may be more beneficial than immunotherapy added to chemotherapy.
引用
- Varlotto J, Voland R, DeCamp M, et al. Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era. Radiother Oncol. 2024. PMID: 39537032. doi:10.1016/j.radonc.2024.110619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。